The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.
about
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trialsSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabContinuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.Methods and challenges in quantitative imaging biomarker developmentThe imaging viewpoint: how imaging affects determination of progression-free survivalThe power of phase II end-points for different possible mechanisms of action of an experimental treatmentCNS Anticancer Drug Discovery and Development Conference White Paper.Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume.Overview: progression-free survival as an endpoint in clinical trials with solid tumors.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study.A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.
P2860
Q26797292-7BFAE4BC-53FE-4FD8-BBF2-5248D7F9CF20Q29620596-CE1FC965-07AD-4DD4-8BF0-CDAF56F9888DQ33567889-AEE97253-5DF1-4070-ABE0-9CB9A59B99FFQ34040130-CE80FD38-0EB1-4BD8-BCA2-36C2056B6C74Q34439059-740C129C-7960-427E-8F97-47FB12C47EF7Q34648114-E0E8F441-AE9A-4DB5-BB5B-C7B58EBF5096Q34719348-D044896B-D9E9-44DA-93B1-F827C64377AEQ35619065-537DAE2B-453C-426D-B12A-8DACB33D343BQ36089590-F12B7E07-4530-4F38-98AD-D2C76EA43576Q37495153-A72D8003-FB88-4B5B-B154-7B6E85A03C76Q38106563-6F3B9E66-2EA7-4F2A-9172-FFF6FD83A74DQ38178093-181B6BD3-1561-4B54-B75B-3C91154105BCQ38849150-11C16CE5-5869-4796-8828-B632D5114224Q38968702-9C1888EE-E407-4EDB-AB9F-5CE93A7FD789Q38977168-A18887EC-02B3-495F-AB24-A3BBEDBA91EFQ39302674-003281FD-0933-488B-B6E3-BA935D912F54Q42374085-FC2B242B-046F-42B5-90F9-6CF69D611DBBQ47134263-BF7EB385-CCE0-406A-B766-5DB2DF6D47EF
P2860
The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The clinical viewpoint: defini ...... considerations of measurement.
@en
type
label
The clinical viewpoint: defini ...... considerations of measurement.
@en
prefLabel
The clinical viewpoint: defini ...... considerations of measurement.
@en
P2860
P1476
The clinical viewpoint: defini ...... considerations of measurement.
@en
P2093
Liza C Villaruz
Mark A Socinski
P2860
P304
P356
10.1158/1078-0432.CCR-12-2935
P407
P577
2013-05-01T00:00:00Z